Investors often find themselves caught between two competing impulses: chasing high-growth names that trade at eye-watering multiples, or sticking with cheap stocks that might offer little in the way of earnings momentum. The Affordable Growth strategy attempts to bridge that gap. The idea is simple, target companies that are delivering solid top- and bottom-line expansion while still carrying a valuation that hasn't fully priced in that future potential. By setting minimum thresholds for growth, profitability, and financial health, while ensuring valuation scores aren't in distressed territory, the approach aims to uncover stocks with a clearer risk/reward profile.
One name that surfaces from this screen is Globus Medical Inc - A (NYSE:GMED), a medical device company specializing in musculoskeletal solutions. Its fundamental report, accessible in full here, reveals why it might fit the Affordable Growth mold.
Recent Performance
The company has posted impressive historical momentum. Over the last year, earnings per share surged by 27.39%, while revenue climbed 16.65%. Looking back further, the five-year average EPS growth comes in at 22.84% annually, with revenue expanding at an average rate of 30.08% per year. These are not one-off spikes, they point to a business that has consistently delivered.
Looking ahead, analysts project average annual EPS growth of 11.57% over the next several years, with revenue expected to grow at 7.38% per year. While the pace may moderate, the forward estimates still indicate a company expanding faster than the broader market.
Valuation Metrics
Despite the strong growth trajectory, GMED is not priced like a speculative high-flyer. The current Price/Earnings ratio sits at 21.95, which is actually cheaper than roughly 76% of its industry peers in the Health Care Equipment & Supplies sector. For context, the average P/E for the S&P 500 is about 26.54, placing GMED slightly below that benchmark.
Forward earnings tell a similar story. With a Price/Forward Earnings ratio of 19.25, the stock trades at a discount to 80% of its industry competitors and remains in line with the broader market average. Additionally, the Enterprise Value to EBITDA ratio suggests the stock is cheaper than nearly 81% of its peers, while the Price/Free Cash Flow multiple puts it at a discount to about 88% of the industry.
These valuation checks support the Affordable Growth thesis: the market has not yet assigned a premium that fully prices in the company’s expansion prospects.
Growth and Profitability
Growth alone is not enough if a company is burning through cash or operating on thin margins. GMED’s profitability rating of 8 out of 10 reflects consistent performance over time. The company has been profitable each year for the past five years and has maintained positive operating cash flow throughout that period.
Key margins are strong:
- Profit Margin: 18.30% (better than 94% of industry peers)
- Operating Margin: 18.30% (outperforms 90% of peers)
- Gross Margin: 67.41% (above 72% of peers)
Return metrics also stand out: Return on Assets at 10.14%, Return on Equity at 11.76%, and Return on Invested Capital at 9.75% each rank among the top quartile of the sector.
Financial Health
A company with high growth but a weak balance sheet can become a distressed story quickly. GMED scores an 8 out of 10 on financial health, a rating that aligns with the Affordable Growth screen's requirement for fundamental stability.
Key solvency and liquidity metrics include:
- Altman-Z Score: 11.39 (far above the danger zone and higher than 90% of peers)
- Debt/Equity Ratio: 0.00 (no debt on the books)
- Current Ratio: 4.26 (strong short-term liquidity)
- Quick Ratio: 2.74 (solid even without inventory)
The company has also reduced its share count over the past year and improved its debt-to-assets ratio, two actions that signal disciplined capital management.
Why This Strategy Matters
The Affordable Growth filter is designed to avoid the extremes. By requiring a growth rating above 7, a valuation score above 5, and decent profitability and health scores, the screen seeks out companies that are firing on most cylinders without being overpriced. GMED meets all of these thresholds: its growth rating stands at 7, valuation at 5, profitability at 8, and health at 8. This isn't a speculative bet on a turnaround, it's a fundamentally sound company with historical proof of expansion and a price tag that doesn't yet reflect the full story.
More Affordable Growth Candidates
The screen used to identify GMED can be run for any investor looking to explore similar opportunities. By applying the same criteria, strong growth, reasonable valuation, and solid financial health, you can filter for additional stocks that match the Affordable Growth profile.
Discover more potential candidates by checking the Affordable Growth screen results.
This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making investment decisions.